Генетические аспекты атерогенных дисплимидемий у больных сахарным диабетом 2 типа
Диссертация
АПРОБАЦИЯ РАБОТЫ. Результаты диссертационной работы доложены и обсуждены на совместном заседании проблемной комиссии «Заболевания сердечно-сосудистой системы, крови и эндокринных органов» и кафедры факультетской терапии СПбГМУ им. акад. И. П. Павлова (02.2009; 09.2009), на заседании проблемной комиссии «Внутренние болезни и другие терапевтические специальности» СПбМАПО (2009), на Европейском… Читать ещё >
Список литературы
- Алмазов В.А., Благосклонная Я. В., Шляхто Е. В., Красильникова Е. И. Метаболический сердечно-сосудистый синдром. СПб.: Издательство СПбГМУ, 1999.-208 с.
- Аметов А.С. Факторы риска сахарного диабета. Роль ожирения // Русский Медицинский Журнал. 2003. — Т. 27. — С. 1477−1479.
- Дедов И.И., Шестакова М. В. Проблема контроля качества диабетологической помощи в России // Сахарный диабет. 2008. — Т. 3 (40).-С. 55−58.
- Дедов И.И., Шестакова М. В. Значимость результатов исследования ADVANCE для контроля сахарного диабета в России // Сахарный диабет. 2009. — Т. 2 (43). — С. 4−5.
- Демидова Т.Ю., Круглова Е. Л. Ожирение, как ключевая и модифицируемая причина развития сахарного диабета 2 типа // Русский Медицинский Журнал. 2009. — Т. 17 (7). — С. 450—458.
- Климов А.Н. Эпидемиология и факторы риска ишемической болезни сердца. Л.: Медицина, 1989. — 176 с.
- Климов А.Н., Ганелина И. Е. Фенотипирование гиперлипидемий. М.: Медицина, 1975. — 47 с.
- Климов А.Н., Никульчева Н. Г. Обмен липидов и липопротеидов и его нарушения. СПб: Питер Ком, 1999. — 512 с.
- Ларионова В.И. Клинико-генетический анализ предрасположенности к развитию атеросклероза у детей и подростков. — Диссертация насоискание ученой степени доктора медицинских наук. СПб., 2005.
- Перова Н.В., Метельская В. А. Метаболические нарушения в патогенезе атеросклероза и методы их коррекции. Москва., 2008. — 64 с.
- Лупанов В.П. Ожирение как фактор риска развития сердечнососудистых катастроф // Русский Медицинский Журнал. — 2003. — Т. 6. -С. 331−337.
- И.Мельниченко Г. А. Ожирение в практике эндокринолога // Русский
- Aalto-Setala K., Weinstock P., Bisgaier C. et al. Further characterization of the metabolic properties of triglyceride- rich lipoproteins from human and mouse apoC-III transgenic mice // J. Lipid Res. 1996. — Vol. 37. — P. 1802−1811.
- Adiels M., Olofsson S., Taskinen M. et al. Diabetic dyslipidaemia // С шт. Opin. Lipidol. 2006. — Vol. 17. — P. 238−246.
- Adiels M., Olofsson S., Taskinen M. et al. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome // Arterioscler. Thromb. Vase. Biol. 2008. — Vol. 28. — P. 12 251 236.
- Albert Т., Duchateau P., Deeb S. et al. Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL // J. Lipid Res. 2005. — Vol. 46. — P. 469−474.
- Alborn W., Johnson M., Prince M. et al. Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum // Clinical Chemistry. 2006. — Vol. 52 (3). — P. 514−517.
- Alborn W., Prince M., Konrad R. Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes // Clinica Chimica Acta. 2007. — Vol. 378 (1−2). — P. 154−158.
- Altomonte J., Cong L., Harbaran S. et al. Foxol mediates insulin action on apoC-III and triglyceride metabolism // J. Clin. Invest. 2004. — Vol. 114 (10).-P. 1493−1503.
- Anber V., Griffin В., McConnell M. et al. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans // Atherosclerosis. 1996. — Vol. 124 (2).-P. 261−271.
- Angotti E., Mele E., Costanzo F. et al. A polymorphism (G—>A transition) in the -78 position of the apolipoprotein A-I promoter increases transcription efficiency //J. Biol. Chem. 1994. — Vol. 269 (26). — P. 17 371−17 374.
- Aouizerat В., Allayee H., Bodnar J. et al. Novel genes for familial combined hyperlipidemia // Curr. Opin. Lipidol. 1999. — Vol. 10 (2). — P. 113−122.
- Aouizerat В., Kulkarni M., Heilbron D. et al. Genetic analysis of a polymorphism in the human apoA-V gene // J. Lipid Res. 2003. — Vol. 44.-P. 1167−1173.
- Austin M., Talmud P., Farin F. et al. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans // Biochim. Biophys. Acta. 2004. — Vol. 1688 (1). — P. 1−9.
- Baroukh N., Bauge E., Akiyama J. et al. Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice // Arterioscler. Thromb. Vase. Biol. 2004. — Vol. 24. — P. 1297−1302.
- Barter P. Metabolic abnormalities: high-density lipoproteins // Endocrinol. Metab. Clin. N. Am. 2004. — Vol. 32. — P. 393−403.
- Barter P., Chang L., Newnham H. et al. The interaction of cholesteryl ester transfer protein and unesterified fatty acids promote // Biochim. Biophys. Acta.- 1990.-Vol. 1045.-P. 81−89.
- Baum L., Tomlinson В., Thomas G. APOA5−1131T>C polymorphism is associated with triglyceride levels in Chinese men // Clin. Genet. — 2003. — Vol. 63 (5).-P. 377−379.
- Becker A., Bos G., de Vegt F. et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study // Eur. Heart J. 2003. — Vol. 24. — P. 1406−1413.
- Beckman J., Creager M., Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management // JAMA. 2002. — Vol. 287 (19).-P. 2570−2581.
- Berneis К., Krauss R. Metabolic origins and clinical significance of LDL heterogenity // J. Lipid Res. 2002. — Vol. 43. — P. 1363−1379.
- Bjornheden Т., Babyi A., Bondjers G. et al. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system // Atherosclerosis. 1996. — Vol. 123 (1). — P. 43−56.
- Blake G., Otvos J., Rifai N. et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women // Circulation. 2002. — Vol. 106.-P. 1930−1937.
- Blin N., Stafford D. A general method for isolation of high molecular weight DNA from eukaryotes // Nucleic Acids Research. — 1976. Vol. 3 (9). — P. 2303−2308.
- Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM//Diabetes. 1997.-Vol. 46 (l).-P. 3−10.
- Boden G. Pathogenesis of type 2 diabetes. Insulin resistance // Endocrinol. Metab. Clin. N. Am. 2001. — Vol. 30. — P. 801−815.
- Brunzell J. Increased apoB in small dense LDL particles predicts premature coronary artery disease // Arterioscler. Thromb. Vase. Biol. 2005. — Vol. 25.-P. 474—475.
- Campos H., Arnold K., Balestra M. et al. Differences in receptor binding of LDL subfractions // Arterioscler. Thromb. Vase. Biol. 1996. — Vol. 16. — P. 794−801.
- Campos H., Genest J. Jr, Blijlevens et al. Low density lipoprotein particle size and coronary artery disease // Arterioscler. Thromb. Vase. Biol. 1992. -Vol. 12.-P. 187−195.
- Cardona F., Guardiola M., Queipo-Ortuno M. et al. The -1131T>C SNP ofthe AP0A5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: A postprandial study // Atherosclerosis. -2009. Vol. 206 (1). — P. 148−152.
- Carmena-Ramon R., Ordovas J., Ascaso J. et al. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia // Atherosclerosis. 1998. — Vol. 139 (1). — P. 107−113.
- Carr M., Brunzell J. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk // J. Clin. Endocrinol. Metab. 2004. — Vol. 89 (6). — P. 2601−2607.
- Chahil Т., Ginsberg H. Diabetic dyslipidemia // Endocrinol. Metab. Clin. N. Am. 2006. — Vol. 35. — P. 491−510.
- Chait A., Brazg R., Tribble D. et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern В // Am. J. Med. 1993. — Vol. 94 (4).-P. 350−356.
- Chan D., Watts G., Nguyen M. et al. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics // Arterioscler. Thromb. Vase. Biol. 2006. — Vol. 26. — P. 590−596.
- Charriere S., Bernard S., Aqallal M. et al. Association of APOA5 -1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients // Clin. Chim. Acta. -2008. Vol. 394 (1−2). — P. 99−103.
- Chhabra S., Narang R., Lakshmy R. et al. Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD // Mol. Cell. Biochem. 2004. -Vol. 259 (1−2).-P. 59−66.
- Chien K., Chen M., Hsu H. et al. Genetic association study of APOA1/C3/A4/A5 gene cluster and haplotypes on triglyceride and HDLcholesterol in a community-based population // Clin. Chim. Acta. 2008. -Vol. 388 (1−2).-P. 78−83.
- Clavey V., Lestavel-Delattre S., Copin C. et al. Modulation of lipoprotein В binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E // Arterioscler. Thromb. Vase. Biol. 1995. — Vol. 15. — P. 963−971.
- Clay M., Newnham H., Forte T. et al. Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL // Biochim. Biophys. Acta. 1992. -Vol. 1124.-P. 52−58.
- Dahlback В., Nielsen L. Apolipoprotein M a novel player in high-density lipoprotein metabolism and atherosclerosis // Curr. Opin. Lipidol. — 2006. -Vol. 17(3).-P. 291−295.
- Dallinga-Thie G., van Tol A., Hattori H. et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes // Diabetologia. 2006. — Vol. 49 (7). — P. 1505−1511.
- Dammerman M., Sandkuijl L., Halaas J. et al. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms // Proc. Nat. Acad. Sci. 1993. -Vol. 90 (10). — P. 4562^4566.
- De Fronzo R., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease // Diabetes Care. 1991. — Vol. 14 (3).-P. 173−194.
- Dorfmeister В., Cooper J., Stephens J. et al. The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes // Biochim. Biophys. Acta. 2007. -Vol. 1772 (3).-P. 355−363.
- Drexel H., Amann F., Beran J. et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis // Circulation. 1994. — Vol. 90. — P. 2230−2235.
- Duvillard L., Pont F., Floretin E. et al. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus // Atherosclerosis. 2000. — Vol. 152 (1). — P. 229−237.
- Elosua R., Ordovas J., Cupples L. et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study // J. Lipid Res. 2006. — Vol. 47. — P. 990−996.
- Endo K., Yanagi H., Araki J. et al. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren // Hum. Genet. 2002. — Vol. 111 (6). — P. 570−572.
- Ferns G., Garlton D. Haplotypes of the human apoprotein AI-CIII-AIV gene cluster in coronary atherosclerosis // Hum. Genet. — 1986. — Vol. 73 (3). — P. 245−249.
- Fisher E., Ginsberg H. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins // J. Biol. Chem. — 2002. Vol. 277 (20). — P. 17 377−17 380.
- Forte Т., Shu X., Ryan R. et al. The ins (cell) and outs (plasma) of apolipoprotein A-V // J. Lipid Res. 2009. — Vol. 50. — P. S150-S155.
- Fournier N., Atger V., Paul J. et al. Human apoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum // Arterioscler. Thromb. Vase. Biol. 2000. -Vol. 20.-P. 1283−1292.
- Fox C., Coady C., Sorlie P. et al. Increasing cardiovascular disease burden due to diabetes mellitus. The Framingham Heart Study // Circulation. -2007. Vol. 115.-P. 1544−1550.
- Frances F., Corella D., Sorli J. et al. Validating a rapid method for detecting common polymorphisms in the APOA5 gene by melting curve analysis using LightTyper // Clinical Chemistry. 2005. — Vol. 51. — P. 1279−1282.
- Friedewald W., Levy R., Fredrikson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge // Clinical Chemistry. 1972. — Vol. 18 (6). — P. 499−502.
- Fruchart-Najib J., Bauge E., Niculescu S. et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5 // Biochim. Biophys. Res. Comm. 2004. — Vol. 319 (2). — P. 397−404.
- Gangabadage C., Zdunek J., Tessari M. et al. Structure and dynamics of human apolipoprotein CIII // J. Biol. Chem. 2008. — Vol. 283 (25). — P.17 416−17 427.
- Gao J., Wei Y., Huang Y. et al. The expression of intact and mutant human apoAT/CIII/AIV/AV gene cluster in transgenic mice // J. Biol. Chem. -2005. Vol. 280 (13). — P. 12 559−12 566.
- Gardner C., Fortmann S., Krauss R. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women // JAMA. 1996. — Vol. 276 (11). — P. 875−881.
- Garvey W., Kwon S., Zheng D. et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance // Diabetes. 2003. — Vol. 52. — P. 453−462.
- Genoux A., Dehondt H., Helleboid-Chapman A. et al. Transcriptional regulation of apolipoprotein A5 gene expression by nuclear receptor RORa // Arterioscler. Thromb. Vase. Biol. 2005. — Vol. 25. — P. 1186−1192.
- Ginsberg H. Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia // J. Clin. Endocrinol. Metab. 2006. -Vol. 91(2).-P. 383−392.
- Ginsberg H. New perspectives in atherogenesis. Role of abnormal triglyceride-rich lipoprotein metabolism // Circulation. 2002. — Vol. 106. — P.2137−2142.
- Ginsberg H. Insulin resistance and cardiovascular disease // J. Clin. Invest. -2000. Vol. 106 (4). — P. 453−458.
- Ginsberg H. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis // Diabetes Care. 1991. — Vol. 14 (9). — P. 839−855.
- Girona J., Guardiola M., Cabre A. et al. The apolipoprotein A5 gene -1131T—>C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients // Clin. Chem. Lab. Med. 2008. — Vol. 46. — P. 453−457.
- Goldstein B. Insulin resistance as the core defect in type 2 diabetes mellitus // Am. J. Cardiol. 2002. — Vol. 90 (5, Suppl. 1). — P. 3−10.
- Grallert H., Sedlmeier E., Huth C. et al. APOA5 variants and metabolic syndrome in Caucasians // J. Lipid Res. 2007. — Vol. 48. — P. 2614−2621.
- Groenendijk M., Cantor R., de Bruin T. et al. The apoAI-CIII-AIV gene cluster // Atherosclerosis. 2001. — Vol. 157. — P. 1−11.
- Grundy S., Benjamin I., Burke G. et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association // Circulation. 1999. — Vol. 100. — P. 1134−1146.
- Grundy S. Small LDL, atherogenic dyslipidemia, and metabolic syndrome // Circulation. 1997. — Vol. 95. — P. 1−4.
- Haffner S. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance // Am. J. Cardiol. 2002. — Vol. 90 (8 Suppl.). — P. 55−61.
- Care. 2009. — Vol. 32 (1). — P. 184−186.
- Hamon S., Kardia S., Boerwinkle E. et al. Evidence for consistent intragenic and intergenic interactions between SNP effects in the APOA1 /СЗ/А4/А5 gene cluster // Hum. Hered. 2006. — Vol. 61. — P. 8796.
- Harchaoui K., Arsenault В., Franssen R. et al. High-density lipoprotein particle size and concentration and coronary risk // Ann. Int. Med. 2009. — Vol. 150 (2). — P. 84−93.
- Henneman P., Schaap F., Havekes L. et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism // Atherosclerosis. 2007. — Vol. 193 (l).-P. 129−134.
- Hegele R., Pollex R. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates // Arterioscler. Thromb. Vase. Biol. 2007. -Vol. 27.-P. 1224−1227.
- Heng C., Low P., Saha N. Variations in the promoter region of the apolipoprotein A-l gene influence plasma lipoprotein (a) levels in Asian Indian neonates from Singapore // Pediatr. Res. — 2001. Vol. 49 (4). — P. 514−518.
- Hirano Т., Hayashi Т., Adachi M. et al. Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease // Metabolism. 2007. — Vol. 56 (4). — P. 462−463.
- Hixson J., Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal // J. Lipid Res. 1990. — Vol. 31.-P. 545−548.
- Hodolugil U., Tanyolac S., Williamson D. et al. Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks // J. Lipid Res. -2006.-Vol. 47.-P. 144−153.
- Hong S., Park W., Lee C. et al. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects // Clinical Chemistiy. 1997. — Vol. 43. — P. 13−17.
- Hubacek J., Horinek A., Skodova Z. et al. Hypertriglyceridemia: interaction between APOE and APOAV variants // Clinical Chemistry. -2005.-Vol. 51.-P. 1311−1313.
- Hubacek J., Lanska V., Skodova Z. et al. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels//Eur. J. Hum. Genet. 2008.-Vol. 16. — P. 135−138.
- Hubacek J. b Skodova Z., Adamkova V. et al. The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction // Clin. Genet. 2004. — Vol. 65 (2). -P. 126−130.
- Hubacek J.2, Kova J., Skodova Z. et al. Genetic analysis of APOAV polymorphisms (Т-1131/C, Serl9/Trp and Vall53/Met): no effect on plasma remnant particles concentrations // Clin. Chim. Acta. 2004. — Vol. 348 (1−2).-P. 171−175.
- International Diabetes Federation. Diabetes epidemic out of control. Press release. Available at: http://www.idf.org/diabetes-epidemic-outcontrol. December 4, 2006.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available at: http://www.idf.org/webdata/docs/IDFMetadeffinal.pdf. International Diabetes Federation, 2006.
- Ishihara M., Kujiraoka Т., Iwasaki T. et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration // J. Lipid Res. 2005. — Vol. 46. — P. 2015−2022.
- Isomaa В., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the Metabolic Syndrome // Diabetes Care. 2001. -Vol. 24 (4).-P. 683−689.
- Ito Y., Azrolan N., O’Connell A. et al. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice // Science. — 1990. Vol. 249 (4970). — P. 790−793.
- Jakel H., Nowak M., Moitrot E. et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-lc // J. Biol. Chem. 2004. — Vol. 279 (44). — P. 45 462−45 469.
- Jong M., Hofker M., Havekes L. Role of ApoCs in lipoprotein metabolism functional differences between ApoCl, ApoC2, and АроСЗ // Arterioscler. Thromb. Vase. Biol. 1999. — Vol. 19. — P. 472−484.
- Juo S., Wyszynski D., Beaty T. et al. Mild association between the A/G polymorphism in the promoter of the apolipoprotein A-I gene and apolipoprotein A-I levels: A meta-analysis // Am. J. Med. Genet. 1999. — Vol. 82 (3).-P. 235−241.
- Kamboh M., Aston C., Nestlerode C. et al. Haplotype analysis of two APOAl/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol // Atherosclerosis. 1996. — Vol. 127 (2). — P. 255−262.
- Kamboh M., Bunker C., Aston C. et al. Genetic association of five apolipoprotein polymorphisms with serum lipoprotein-lipid levels in African blacks // Genet. Epidemiol. 1999. — Vol. 16 (2). — P. 205−222.
- Karathanasis S. Apolipoprotein multigene family: tandem organization of human apolipoprotein Al, CIII, and AIV genes // Proc. Natl. Acad. Sci. USA. 1985. — Vol. 82 (19). — P. 6374−6378.
- Karathanasis S., Yunis I., Zannis V. Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV // Biochemistry. 1986. -Vol. 25.-P. 3962−3970.
- Kee F., Amouyel P., Fumeron F. et al. Lack of association between genetic variations of apo A-I-C-III—A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study // Atherosclerosis. — 1999.-Vol. 145 (1).-P. 187−195.
- Kelley D., Simoneau J. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus // J. Clin. Invest. 1994. -Vol. 94 (6).-P. 2349−2356.
- King H., Aubert R., Herman W. Global burden of diabetes, 19 952 025: Prevalence, numerical estimates, and projections // Diabetes Care. -1998.-Vol. 21 (9).-P. 1414−1431.
- Klos K., Hamon S., Clark A. et al. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study // J. Lipid Res. 2005. — Vol. 46. — P. 564−571.
- Kluger M., Heeren J., Merkel M. Apolipprotein A-V: an important regulator of triglyceride metabolism // J. Inherit. Metab. Dis. 2008. — Vol. 31 (2).-P. 281−288.
- Kovar J., Adamkova V. Lipoprotein lipase activity determined in vivo is lower in carriers of apolipoprotein A-V gene variants 19W and -1131С // Physiol. Res. -2008. Vol. 57.-P. 555−561.
- Kowal R., Herz J., Weisgraber K. et al. Opposing effects of apolipoproteins E and С on lipoprotein binding to low density lipoprotein receptor-related protein // J. Biol. Chem. 1990. — Vol. 265 (18). — P. 10 771−10 779.
- Krauss R. Atherogenicity of triglyceride-rich lipoproteins // Am. J. Cardiol. 1998. — Vol. 81 (4, Suppl. 1). — P. 13B-17B.
- Krauss R. Lipids and lipoproteins in patients with type 2 diabetes // Diabetes Care. 2004. — Vol. 27. — P. 1496−1504.
- Krauss R., Siri P. Metabolic abnormalities: triglyceride and low-density lipoprotein // Endocrinol. Metab. Clin. N. Am. 2004. — Vol. 33. -P. 405−415.
- Krauss R., Williams P., Lindgren F. et al. Coordinate changes in levels of human serum low and high density lipoprotein subclasses in healthy men // Arterioscler. Thromb. Vase. Biol. 1988. — Vol. 8. — P. 155— 162.
- Kreisberg R. Diabetic dyslipidemia // Am. J. Cardiol. 1998. — Vol. 82 (12, Suppl. 1). — P. 67U-73U.
- Lai C., Amett D., Corella D. et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants // Arterioscler. Thromb. Vase. Biol. 2007. — Vol. 27. — P. 1417−1425.
- Lai C., Demissie S., Cupples L. et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study // J. Lipid Res. 2004. — Vol. 45. — P. 2096−2105.
- Lai C., Parnell L., Ordovas J. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk // Curr. Opin. Lipidol. -2005.-Vol. 16 (2).-P. 153−156.
- Lai C., Tai E., Tan C. et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore // J. Lipid Res. 2003. — Vol. 44. — P. 2365−2373.
- Lamant M., Smih F., Harmancey R. et al. ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart // J. Biol. Chem. 2006. — Vol. 281 (47). — P. 36 289−36 302.
- Lamarche B.2, Moorjani S., Cantin B. et al. Associations of HDL2 and HDL3 subtractions with ischemic heart disease in men prospective results from the Quebec Cardiovascular Study // Arterioscler. Thromb. Vase. Biol. -1997.-Vol. 17.-P. 1098−1105.
- Larson I., Ordovas J., Barnard J. et al. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels // Clin. Genet. 2002. — Vol. 61 (3). — P. 176−184.
- Laws A., Reaven G. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations // Journal of Internal Medicine. — 1992. Vol. 231 (l).-P. 25−30.
- Lee K., Ayyobi A., Frohlich J. et al. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but not a risk factor for coronary artery disease // Atherosclerosis. 2004. — Vol. 176 (l).-P. 165−172.
- Lewis G., Rader D. New insights into the regulation of HDL metabolism and reverse cholesterol transport // Circ. Res. — 2005. Vol. 96. -P. 1221−1232.
- Li G., Wang J., Yan S. et al. Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and apolipoproteins levels in a Chinese population // Clin. Genet. 2004. — Vol. 65 (6).-P. 470−476.
- Li X., Xu Y., Ding Y. et al. Polymorphism of apolipoprotein A5 is a risk factor for cerebral infarction in type 2 diabetes // Journal of Huazhong University of Science and Technology. 2008. — Vol. 28 (6). — P. 653−656.
- Lind U., Nilsson Т., McPheat J. et al. Identification of the human ApoAV gene as a novel RORa target gene // Biochim. Biophys. Res. Commun.- 2005. -Vol. 330 (1). P. 233−241.
- Lookene A., Beckstead J., Nilsson S. et al. Apolipoprotein A-V-heparin interactions. Implications for plasma lipoprotein metabolism // J.
- Biol. Chem. 2005. — Vol. 280 (27). — P. 25 383−25 387.
- Maasz A., Kisfali P., Szolnoki Z. et al. Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke // Journal of Neurology. 2008. — Vol. 255 (5). — P. 649−654.
- Maeda N., Li H., Lee D. et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia // J. Biol. Chem. 1994. — Vol. 269 (38). — P. 23 610−23 616.
- Mahley R., Ji Z. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E // J. Lipid Res. 1999. — Vol. 40. — P. 1−16.
- Malmberg K., Yusuf S., Gerstein H. et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction//Circulation.-2000.-Vol. 102.-P. 1014−1019.
- Mansouri R., Bauge E., Gervos P. et al. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia // Circulation Research. 2008. — Vol. 103. — P. 450−453.
- Mar R., Pajukanta P., Allayee H. et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia // Circulation Research. 2004. — Vol. 94. — P. 993−999.
- Martin S., Nicaud V., Humphries S. et al. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges // Biochim. Biophys. Acta. 2003. -Vol. 1637 (3). — P. 217−225.
- Martin-Campos J., Rico N., Bonet R. et al. Apolipoprotein A5 S19W may play a role in dysbetalipoproteinemia in patients with the Apo E2/E2 Genotype // Clinical Chemistry. 2006. — Vol. 52. — P. 1974−1975.
- Mata P., Lopez-Mirandab J., Pocovic M. et al. Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation // Atherosclerosis. — 1998. — Vol. 137 (2). P. 367−376.
- Matthews D., Hosker J., Rudenski A. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. 1985. — Vol. 28 (7). -P. 412−419.
- McNamara J., Jenner J., Li Z. et al. Change in LDL particle size is associated with change in plasma triglyceride concentration // Arterioscler. Thromb. Vase. Biol. 1992. — Vol. 12. — P. 1284−1290.
- Merkel M., Eckel R., Goldberg I. Lipoprotein lipase: genetics, lipid uptake, and regulation // J. Lipid Res. 2002. — Vol. 43. — P. 1997−2006.
- Merkel M., Loeffler В., Kluger M. et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceriderich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase // J. Biol. Chem. 2005. — Vol. 280 (22).-P. 21 553−21 560.
- Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group // Diabetes Care. 1998. — Vol. 21 (1). — P. 69−75.
- Moreno-Luna R., Perez-Jimenez F., Marin C. et al. Two independent apolipoprotein A5 haplotypes modulate postprandial lipoprotein metabolismin a healthy Caucasian population // J. Clin. Endocrinol. Metab. 2007. — Vol. 92 (6).-P. 2280−2285.
- Morrish N., Wang S., Stevens L. et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes // Diabetologia.-2001.-Vol.44 (Suppl. 2).-P. S14−21.
- Morcillo S., Gardona F., Rojo-Martinez G. et al. Association between Mspl polymorphism of the APO Al gene and type 2 diabetes mellitus // Diabet. Med. 2005. — Vol. 22 (6). — P. 782−788.
- Nabika Т., Nasreen S., Kobayashi S. et al. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese // Atherosclerosis. 2002. — Vol. 165 (2). — P. 201−204.
- Nelbach L., Shu X., Konrad R. et al. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice // J. Lipid Res. 2008. — Vol. 49. — P. 572−580.
- Niculescu L., Fruchart-Najib J., Fruchart J. et al. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome // Clin. Chem. Lab. Med. 2007. — Vol. 45. — P. 1133−1139.
- Olano-Martin E., Abraham E., Gill-Garrison R. et al. Influence of apoA-V gene variants on postprandial triglyceride metabolism: impact of gender // J. Lipid Res. 2008. — Vol. 49. — P. 945−953.
- Oliva C., Pisciotta L., Volti G. et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia // Arterioscler. Thromb. Vase.
- Biol. 2005. — Vol. 25. — P. 411−417.
- Oram J., Heinecke J. ATP-binding cassette transporter Al: a cell cholesterol exporter that protects against cardiovascular disease // Physiol. Rev. 2005. — Vol. 85. — P. 1343−1372.
- Ordovas J. Genetic interactions with diet influence the risk of cardiovascular disease // Am. J. Clinical Nutrition. 2006. — Vol. 83 (2). -P. 443S-446S.
- Paccaud F., Schluter-Fasmeyer V., Wietlisbach V. et al. Dyslipidemia and abdominal obesity: an assessment in three general populations // J. Clin. Epidemiol. 2000. — Vol. 53 (4). — P. 393−400.
- Paigen В., Ishida В., Verstuyft J. et al. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice // Arteriosclerosis. 1990. — Vol. 10. — P. 316−323.
- Pascot A., Lemieux I., Prud’homme D. et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity // J. Lipid Res. 2001. — Vol. 42. — P. 2007−2014.
- Paul-Hayase LI., Rosseneu M., Robinson D. et al. Polymorphisms of apo AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo Al, apo CIII and apo AIV concentrations // Hum. Genet. 1992. -Vol. 88 (4).-P. 439−446.
- Pennacchio L., Olivier M., Hubasek J. et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing//Science. -2001. Vol. 294 (5540). — P. 169−173.
- Pennacchio L., Olivier M., Hubacek J. et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels // Hum. Mol. Genet. 2002. — Vol. 11 (24). — P. 3031−3038.
- Pennacchio L., Rubin E. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice // Arterioscler. Thromb. Vase. Biol. 2003. — Vol. 23. — P. 529−534.
- Pietzsch J., Julius U., Nitzsche S. et al. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance // Diabetes. 1998. — Vol. 47 (12). — P. 1928−1934.
- Price W., Kitchin A., Burgon P. et al. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease // Lancet. 1989. — Vol. 333 (8652). — P. 1407−1411.
- Prieur X., Huby Т., Rodriguez J. et al. Apolipoprotein AV: gene expression, physiological role in lipid metabolism and clinical relevance // Future Lipidology. 2008. — Vol. 3 (4). — P. 371−384.
- Prieur X.2, Huby Т., Coste H. et al. Thyroid hormone regulates the hypotriglyceridemic gene APOA5 // J. Biol. Chem. 2005. — Vol. 280 (30). -P. 27 533−27 543.
- Pruneta-Deloche V., Ponsin G., Groisne L. et al. Postprandial increase of plasma apoAV concentrations in type 2 diabetic patients // Atherosclerosis. -2005. Vol. 181 (2). — P. 403105.
- Qi L., Liu S., Rifai N. et al. Associations of the apolipoprotein APOA1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes // Atherosclerosis. 2007. — Vol. 192 (1). -P. 204−210.
- Qu S., Perdomo G., Su D. et al. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice // J. Lipid Res. 2007. — Vol. 48.-P. 1476−1487.
- Reasner C. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors // Journal of Cardiovascular Pharmacology. 2008. — Vol. 52 (2). — P. 136−144.
- Reaven G. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profde: the price paid to maintain glucose homeostasis in insulin-resistant individuals // Endocrinol. Metab. Clin. N. Am. 2005. — Vol. 34. — P. 49−62.
- Reguero J., Cubero G., Batalla A. et al. Apolipoprotein Al gene polymorphisms and risk of early coronary disease // Cardiology. 1998.1. Vol. 90.-P. 231−235.
- Rensen P., van Dijlc K., Havekes L. et al. Apolipoprotein AV. Low concentration, high impact // Arterioscler. Thromb. Vase. Biol. 2005. -Vol. 25.-P. 2445−2447.
- Ribalta J., Figuera L., Fernandez-Ballart J. et al. Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia // Clinical Chemistry. 2002. — Vol. 48. — P. 1597−1600.
- Rigoli L., Raimondo G., Benedetto A. et al. Apolipoprotein AI-CIII-AIV genetic polymorphisms and coronary heart disease in type 2 diabetes mellitus // Acta Diabetol. 1995. — Vol. 32 (4). — P. 251−256.
- Rodrigo E., Gonzalez-Lamuno D., Ruiz J. et al. Apolipoprotein C-III and E polymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation // Am. J. Transplant. 2002. — Vol. 2 (4).-P. 343−348.
- Rubin E., Krauss R., Spangler E. et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al // Nature. -1991.-Vol. 353.-P. 265−267.
- Rubins H., Robins S., Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol //N. Engl. J. Med. 1999. — Vol. 341. — P. 410−418.
- Ryden L., Standi E., Baitnik M. et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary // European Heart Journal. 2007. — Vol. 28. — P. 88−136.
- Savage D., Petersen K., Shulman G. Disordered lipid metabolism and pathogenesis of insulin resistance // Physiol. Rev. 2007. — Vol. 87. — P. 507−520.
- Schaap F., Nierman M., Berbee J. et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia // J. Lipid Res. 2006. — Vol. 47. — P. 2333−2339.
- Schaefer J., Sattler A., Hackler B. et al. Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor // Clinical Chemistry. 2004. — Vol. 50. — P. 2214.
- Schultze A., Alborn W., Newton R. et al. Administration of PPARa agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio // J. Lipid Res. 2005. — Vol. 46. — P. 15 911 595.
- Sepehmia В., Kamboh M., Adams-Campbell L. et al. Genetics studies of human apolipoproteins // Hum. Genet. 1989. — Vol. 82 (2). — P. 118— 122.
- Shanker J., Perumal G., Rao V. et al. Genetic studies of APOA1-C3-A5 gene cluster in Asian Indians with premature coronary artery disease // Lipids in Health and Disease. 2008. — Vol. 7:33. Available from: http://www. lipidworld.com/ content/7/1/33.
- Shoulders C., Harry P., Lagrost L. et al. Variation at the apo AI/CIII/A1V gene complex is associated with elevated plasma levels of apo CIII // Atherosclerosis. 1991. — Vol. 87 (2). — P. 239−247.
- Shoulders C., Grantham Т., North J. et al. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children // Hum. Genet. — 1996. -Vol. 98 (5).-P. 557−566.
- Shu X., Chan J., Ryan R. et al. Apolipoprotein A-V association with intracellular lipid droplets // J. Lipid Res. 2007. — Vol. 48. — P. 1445−1450.
- Shu X., Ryan R., Forte T. Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment // J. Lipid Res. -2008.-Vol. 49.-P. 1670−1676.
- Sorkin S., Forestiero F., Hirata M. et al. APOA 1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals // Clin. Chem. Lab. Med. 2005. — Vol. 43 (12).-P. 1339−1345.
- Sprecher D. Triglycerides as a risk factor for coronary artery disease // Am. J. Cardiol. 1998. — Vol. 82 (12, Suppl. 1). — P. 49U-56U.
- Stamler J., Vaccaro O., Neaton J. et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial // Diabetes Care. 1993. — Vol. 16 (2). — P. 434 444.
- Stan S., Delvin E., Lambert M. et al. Apo A-IV: an update on regulation and physiologic functions // Biochim. Biophys. Acta. 2003. — Vol. 1631 (2).-P. 177−187.
- Stein O., Stein Y. Lipid transfer proteins (LTP) and atherosclerosis // Atherosclerosis. 2005. — Vol. 178 (2). — P. 217−230.
- Steiner G. Atherosclerosis in type 2 diabetes: a role for fibrate therapy? // Diabetes and Vascular Disease Research. 2007. — Vol. 4 (4). — P. 368−374.
- Steinmetz A., Barbaras R., Ghalim N. et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells // J. Biol. Chem. 1990. — Vol. 265 (14). — P. 7859−7863.
- Sundl I., Guardiola M., Khoschsorur G. et al. Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene -1131T>C variant and associations with plasma lipids and lipid peroxidation // J. Lipid
- Res. 2007. — Vol. 48. — P. 2506−2513.
- Surguchov A., Page G., Smith L. et al. Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and Hypertriglyceridemia // Arterioscler. Thromb. Vase. Biol. 1996. — Vol. 16. — P. 941−947.
- Szalai C., Keszei M., Duba J. et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease // Atherosclerosis. — 2004. Vol. 173 (1).-P. 109−114.
- Tall A. Plasma cholesteryl ester transfer protein // J. Lipid Res. -1993. Vol. 34. — P. 1255−1274.
- Talmud P. Rare APOA5 mutations Clinical consequences, metabolic and functional effects. An ENID review // Atherosclerosis. — 2007. — Vol. 194 (2). — P. 287−292.
- Talmud P., Humphries S. Apolipoprotein C-III gene variation and dyslipidaemia // Curr. Opin. Lipidol. 1997. — Vol. 8 (3). — P. 154−158.
- Talmud P., Hawe E., Martin S. et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides // Hum. Mol. Genet. 2002. — Vol. 11 (24). — P. 3039−3046.
- Talmud P., Martin S., Taskinen M. et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study // J. Lipid Res. 2004. — Vol. 45. — P. 750 756.
- Talmud P., Palmen J., Putt W. et al. Determination of the functionality of common APOA5 polymorphisms // J. Biol. Chem. 2005. — Vol. 280 (31).-P. 28 215−28 220.
- Tan С., Forster L., Caslake M. et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subtraction patterns in normolipidemic men and women // Arterioscler. Thromb. Vase. Biol. -1995.-Vol. 15.-P. 1839−1848.
- Taskinen M. Diabetic dyslipidaemia: from basic research to clinical practice // Diabetologia. 2003. — Vol. 46. — P. 733−749.
- Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report // Circulation. -2002.-Vol. 106.-P. 3143−3421.
- Tribble D., Holl L., Wood P. et al. Variations in oxidative susceptibility among six low density lipoprotein subtractions of differing density and particle size // Atherosclerosis. 1992. — Vol. 93 (3). — P. 189 199.
- Turner R., Millns H., Neil H. et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) // BMJ. 1998. — Vol. 316. — P. 823−828.
- Tuteja R., Tuteja N., Melo C. et al. Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition // FEBS Lett. 1992. — Vol. 304 (1). — P. 98−101.
- Tybjaerg-Hansen A., Nordestgaard В., Gerdes L. et al. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis // Atherosclerosis. 1993. — Vol. 100 (2). — P. 157−169.
- Vaessen S., Dallinga-Thie G., Ross C. et al. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels // J. Lipid Res. 2009. — Vol. 50. — P. 880−884.
- Vaessen S., Schaap F., Kuivenhoven J. et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic
- Vu-Dak N., Gervois P., Jakel H. et al. Apolipoprotein A5 a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor activators // J. Biol. Chem. 2003. — Vol. 278 (20).-P. 17 982−17 985.
- Wang X., Badenhop R., Humphrey K. et al. С to T and/or G to A transitions are responsible for loss of a Mspl restriction site at the 5'-end of the human apolipoprotein Al gene // Hum. Genet. — 1995. Vol. 95 (4). — P. 473−474.
- Wang X. i, Badenhop R., Humphrey K. et al. New Mspl polymorphism at +83 bp of the human apolipoprotein Al gene: association with increased circulating high density lipoprotein cholesterol levels // Genet. Epidemiol. 1996.-Vol. 13 (l).-P. 1−10.
- Wang X.2, Liu S., McCredie R. et al. Polymorphisms at the 5'-end of the apolipoprotein Al gene and severity of coronary artery disease // J. Clin. Invest. 1996. — Vol. 98 (2). — P. 372−377.
- Watson Т., Caslake M., Freeman D. et al. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects // Arterioscler. Thromb. Vase. Biol. 1994. — Vol. 14. — P. 902 910.
- Weinberg R., Anderson R., Cook V. et al. Interfacial exclusion pressure determines the ability of apolipoprotein A-IV truncation mutants to activate cholesterol ester transfer protein // J. Biol. Chem. 2002. — Vol. 27 724.-P. 21 549−21 553.
- Weinberg R., Cook V., Beckstead J. et al. Structure and interfacial properties of human apolipoprotein A-V // J. Biol. Chem. 2003. — Vol. 278 (36).-P. 34 438−34 444.
- Whiteley L., Padmanabhan S., Hole D. et al. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey // Diabetes Care. 2005. -Vol. 28.-P. 1588−1593.
- Wild S., Roglic G., Green A. et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030 // Diabetes Care. -2004. Vol. 27 (5). — P. 1047−1053.
- Wong K., Ryan R. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation // Curr. Opin. Lipidol. 2007. -Vol. 18(3).-P. 319−324.
- World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). Available at: http://whqlibdoc.who.int/trs/WHOTRS894.pdf. World Health Organization. Geneva, 2000.
- Yamada Y., Kato K., Hibino T. Prediction of genetic risk for metabolic syndrome // Atherosclerosis. 2007. — Vol. 191 (2). — P. 298 304.
- Yan S., Cheng X., Song Y. et. al. Apolipoprotein A5 gene polymorphism -113 IT—>C: association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese // Clin. Chem. Lab. Med.-2005.-Vol. 43 (6).-P. 607−612.
- Zambon A., Austin M., Brown B. et al. Effect of hepatic lipase on LDL in normal men and in those with coronary artery disease // Arterioscler. Thromb. Vase. Biol. 1993. — Vol. 13. — P. 147−153.
- Zannis V., Kan H., Kritis A. et al. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo // Curr. Opin. Lipidol.-2001.-Vol. 12 (2).-P. 181−207.
- Zeng Q., Dammerman M., Takada Y. et al. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population // Hum. Genet. 1995. — Vol. 95 (4).-P. 371−375.
- Zimmet P., Alberti K., Shaw J. Global and societal implications of the diabetes epidemic //Nature. 2001. — Vol. 414. — P. 782−787.
- Zou Y., Hu D., Yang X. et al. Relationships among apolipoprotein Al gene polymorphisms, lipid levels and coronary atherosclerosis disease // Chin. Med. J. (Engl.). 2003. — Vol. 116 (5). — P. 665−668.